Jazz Pharmaceuticals plc Stock Price and Value Analysis

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Jazz Pharmaceuticals plc to reach your target.

Target type

JAZZ Free Cash Flow Trend

Free Cash Flow trendline for JAZZ
Free Cash Flow trendline for Jazz Pharmaceuticals plc
CSV

Based on historical returns, we believe that Jazz Pharmaceuticals plc can grow its free cash at a rate of about 21%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a great rate!
  • This company has stable growth.
  • This company is solid.
  • This stock is available at a great discount!
None.
  • This company pays no dividend.

Inside the JAZZ Numbers

JAZZ Price
(Jazz Pharmaceuticals plc stock price per share)
$230.26
[?] JAZZ Fair Price
(based on intrinsic value)
$484.76
[?] JAZZ Safety Price (based on a variable margin of safety) $315.09
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 236% higher than other Healthcare stocks
[?] PE Ratio versus Industry 46% lower than other Drug Manufacturers - General stocks
[?] Cash Yield 3.36%
[?] Free Cash Flow Jitter 13%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,798,338 shares shorted. With 62,246,691 shares available for purchase and an average trading volume over the past 10 trading days of 717,280, it would take at least 8.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 1232524 -15.9
2010 1232524 58.5
2011 1232524 151
2012 1232524 248
2013 1232524 285
2014 1232524 397
2015 1232524 514
2016 1232524 573
2017 1232524 669
2018 1232524 773
2019 1232524 749
2020 1232524 877
2021 1232524 752
2022 1232524 1,246
2023 1232524 1,065
2024 1232524 1,369
2025 1232524 1,320

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 13 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $7,937 million against net income of $4,119 million, or 1.93 times. Net income was negative in 4 of the 17 years, and those years are left out of the ratio.

In 2025, net income was -$356 million and operating cash flow was $1,356 million, so no ratio is shown for that year.

In 2025, capital expenditures were $58.8 million, 4.3% of operating cash flow of $1,356 million, which leaves an estimated $1,297 million after capex. Across the 16 years with reported capex, it averaged 3.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -6.8 -15.9 0.1 n/a
2010 32.8 58.9 0.7 1.80
2011 125 152 1.3 1.21
2012 289 250 6 0.87
2013 216 288 10 1.33
2014 58.4 408 36.3 6.98
2015 330 532 36 1.61
2016 397 592 9.7 1.49
2017 488 693 28.9 1.42
2018 447 799 20.4 1.79
2019 523 776 40.1 1.48
2020 239 900 15 3.77
2021 -330 779 27.6 n/a
2022 -224 1,272 29 n/a
2023 415 1,092 24 2.63
2024 560 1,396 38.1 2.49
2025 -356 1,356 58.8 n/a

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2015 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $9,154 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 9 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $2,117 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $125 million, 9.5% of estimated free cash flow of $1,320 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2015 514 n/a 61.6 61.6 12.0%
2016 573 n/a 278 278 48.6%
2017 669 n/a 98.8 98.8 14.8%
2018 773 n/a 524 524 67.8%
2019 749 n/a 301 301 40.2%
2020 877 n/a 147 147 16.7%
2022 1,246 n/a 0.1 0.1 0.0%
2023 1,065 n/a 270 270 25.3%
2024 1,369 n/a 311 311 22.7%
2025 1,320 n/a 125 125 9.5%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $128 million in 2009 and $4,268 million in 2025, a compound annual growth rate of 24.5% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 4.9% from 2024 to 2025.

Our estimated free cash flow was $1,320 million in 2025, 30.9% of revenue. In 2009 the estimated margin was negative 12.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 128 -15.9 -12.4%
2010 174 58.5 33.6%
2011 272 151 55.4%
2012 586 248 42.3%
2013 872 285 32.6%
2014 1,173 397 33.8%
2015 1,325 514 38.8%
2016 1,488 573 38.5%
2017 1,619 669 41.3%
2018 1,891 773 40.9%
2019 2,162 749 34.7%
2020 2,364 877 37.1%
2021 3,094 752 24.3%
2022 3,659 1,246 34.0%
2023 3,834 1,065 27.8%
2024 4,069 1,369 33.6%
2025 4,268 1,320 30.9%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $1,392 million against total liabilities of $7,341 million, or 19.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 63.0% of total assets in 2025, compared with 77.5% in 2010, a decrease of 14.5 percentage points.

Stockholders equity was $4,319 million in 2025, compared with $30.6 million in 2010, a rise of 14035.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 16.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 136 44.8 105 30.6
2011 254 82.1 60.8 193
2012 1,966 387 845 1,121
2013 2,238 637 943 1,296
2014 3,339 684 1,968 1,371
2015 3,333 989 1,734 1,599
2016 4,800 366 2,923 1,877
2017 5,124 386 2,411 2,713
2018 5,203 310 2,446 2,757
2019 5,539 637 2,428 3,111
2020 6,536 1,058 2,876 3,660
2021 12,299 591 8,333 3,965
2022 10,835 881 7,750 3,086
2023 11,393 1,506 7,656 3,737
2024 12,012 2,413 7,919 4,094
2025 11,659 1,392 7,341 4,319

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $230.26, our model's value equals that price if free cash flow grows an average of 8.5 percent a year over the 10 projection years. Our model assumes 21.3 percent a year for this stock, so the price implies growth of 8.5 percent, which is below the 21.3 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $496 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $184.21 4.0%
Current price $230.26 8.5%
20 percent above the current price $276.31 11.9%
Our model (stored fair price) $484.76 21.3%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

With the price at $230.26, Jazz Pharmaceuticals plc is below both our safe value ($315.09) and our fair value ($484.76).

Only 16 of the 17 fiscal years under Jazz Pharmaceuticals plc's current filer show positive free cash flow.

The latest three years average $1,251 million in free cash flow against $64.5 million for the earliest three, which is a sharp rise.

Free cash flow is fairly steady from year to year, with a variability measure of 13%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Dividends are not in our data for Jazz Pharmaceuticals plc.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 236% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 46% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Jazz Pharmaceuticals plc, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Jazz Pharmaceuticals plc (JAZZ) 14,780 68.1 - 3.4% 53% below
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Corcept Therapeutics Incorporated (CORT) 7,112 48.9 - 0.0% 858% above
Viatris (VTRS) 22,505 - 2.4% - 2% below
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above
Prestige Consumer Healthcare (PBH) 2,352 15.3 - 7.8% 50% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1232524.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 17 years we have.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: JAZZ annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in JAZZ

Does Jazz Pharmaceuticals plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: JAZZ

This example shows how we apply the Trendshare checklist to JAZZ: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 230.26
    • Market cap: $15B
    • EPS: 3.38
  2. Step 2 — Valuation checks

    • P/E: 68.124
    • FCF yield: 3.4%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.